No Detail Found!

Role of intravenous immunoglobulin in iso-immune jaundice in neonate.

Author(s)
Faten Al-Awaysheh Neonatologist Royal Medical Services, Amman, Jordan
Mona Kuwar Neonatologist Royal Medical Services, Amman, Jordan
Raeda Al-Ghananim King Hussein Medical Center (KHMC), Amman, Jordan
A. L. Nisreen King Hussein Medical Center (KHMC), Amman, Jordan
Omyma Al-Jarrah King Hussein Medical Center (KHMC), Amman, Jordan
Abstract
Objective: To show that intravenous immunoglobulin is safe and effective alternative treatment in newborn with iso-immune hemolytic jaundice. Methodology: This study was carried out in neonatal unit in King Hussein Medical Center (KHMC) and Queen Alia Hospital during two years period of all cases who presented with jaundice either RH or ABO iso-immune jaundice in the first day of life. All patients received phototherapy and intravenous immunoglobulin. Results: There were 91 patients with iso-immune jaundice admitted to the neonatal unit in their first day of life. Eighty five patients out of 91 (93.4%) were due to ABO incompatibility. Six patients out of 91 (6.6%) were due to RH incompatibility. Direct coombs test was positive in all cases of RH incompatibility and in 16 cases of ABO incompatibility. Intravenous immunoglobulin (0.5g/kg) was given to all patients over four hours every 24 hours for three doses. Exchange transfusion was done for one patient only (1%). Blood transfusion was given for 22 patients out of 91 (24%). Hospital stay was around 3-4 days in majority of cases. Conclusion: Intravenous immunoglobulin in newborn with ABO or RH hemolytic jaundice is effective in reducing hemolysis, serum bilirubin level and the need for exchange transfusion.
Publication Details
Page(s) 538-541
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 26, Issue: 3, Year: 2010

Request the full text from PASTIC

0

Citations

0

Downloads

54

Views